Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Arvee Laboratories (India) Ltd

Your Vote -

Buy

66.67%

Hold

0.00%

Sell

33.33%

66.67%

6 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Arvee Laboratories (India) Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Arvee Laboratories Q3 net profit down 37.50% at Rs 0.15 cr

    12 Feb 2025, 6:20PM The company reported standalone net profit of Rs 0.15 crore for the quarter ended December 31, 2024 as compared to Rs 0.24 crore in the same period la
  • Arvee Laboratories - Outcome of Board Meeting

    12 Feb 2025, 12:56PM Arvee Laboratories (India) Limited has informed the Exchange regarding Board meeting held on February 12, 2025.
  • Arvee Laboratories - Financial Result Updates

    12 Feb 2025, 12:55PM Arvee Laboratories (India) Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Arvee Laboratories - Board Meeting Intimation

    3 Feb 2025, 11:25AM ARVEE LABORATORIES (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 12-Feb-2025 to inter-alia consider and approve the Unau
  • Arvee Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    16 Jan 2025, 9:10PM As of December 2024, 73.50% is owned by Indian Promoters and 26.50% by Public. <p align=justify> Top five Promoters holding highest number of shares o
  • Arvee Laboratories - Trading Window-XBRL

    30 Dec 2024, 12:56PM ARVEE LABORATORIES (INDIA) LIMITED has informed the Exchange about Closure of Trading Window
  • Arvee Laboratories - Trading Window

    30 Dec 2024, 12:54PM Arvee Laboratories (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Re

Key fundamentals

Evaluate the intrinsic value of Arvee Laboratories (India) Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 30.114 29.0621 27.0733 30.3174 20.8572
Liabilities 30.114 29.0621 27.0733 30.3174 20.8572
Equity 11.02 11.02 11.02 11.02 5.51
Gross Profit 2.9371 7.2815 5.6653 6.0397 6.0213
Net Profit 1.0518 4.119 2.5738 2.6773 2.2269
Cash From Operating Activities 3.6635 2.9289 4.0159 1.7105 10.3335
NPM(%) 3.46 6.71 6.38 5.65 4.9
Revenue 30.3451 61.347 40.3274 47.375 45.4187
Expenses 27.4079 54.0655 34.6621 41.3352 39.3973
ROE(%) 3.61 14.14 8.84 9.19 7.64

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Arvee Laboratories (India) Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Sharda Cropchem Ltd 546.30 0.44 20.18 0.00 35.34 0.55
Amines and Plasticizers Ltd 207.56 -3.66 27.75 0.00 361.94 0.24
Grauer and Weil (India) Ltd 115.60 0.00 32.66 0.00 322.62 0.43
HP Adhesives Ltd 45.32 -3.04 21.28 0.00 111.94 0.00

Company Info

The Company was incorporated as Arvee Laboratories (India) Private Limited under the provisions of the Companies Act, 1956 vide certificate of incorporation dated January 27, 2012 in Ahmedabad, Gujarat. Subsequently, the name of the company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public company vide shareholder's approval dated September 11, 2017 and vide fresh certificate of incorporation dated September 19, 2017. KEY EVENTS AND MILESTONES IN THE HISTORY OF THE COMPANY 2012 - The Company was incorporated as Arvee Laboratories (India) Private Limited. 2013 - Acquired land, building and machineries from Skylink Chemicals Private Limited and started manufacturing unit. - Started construction of its first plant for Thiophene Derivatives. - Completes construction and commissioning of its Thiophene Derivatives Plant. 2014 - Plant inspected and approved by leading India pharmaceutical manufacturer for supply of Thiophene Derivatives. - Started construction of plant for Sulfo and Nitro Derivatives of Isophthalic Acid. - Received ISO 9001:2008 accreditation for NABCB and DAKKS from TUV NORD. - Plant inspected and approved by an American X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer. - Plant inspected and approved by a European X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer. 2015 - Completed construction and commissioning of plant for Nitro Derivatives of Isophthalic Acid. - After receiving inspection approval, our Company gets order for yearly supply of Nitro Derivatives of Isophthalic Acid to leading contrast media manufacturer in the United States of America. - Export to United States of America (USA) started. - Plant inspected and approved by European manufacturer for supply of Thiophene Derivatives. - Export of Thiophene Derivatives started to Europe. 2016 - Receives internal approvals for our Nitro Derivatives of Isophthalic acid from leading XRay contrast media manufacturer in Europe. - Receive approval for our Sulfo Derivatives of Isophthalic acid from a large polymer manufacturer in the United States of America and received yearly order for supply of Sulfo Derivatives to the USA. - Crossed turnover of Rs. 25 crores. 2017 - Plant inspected and approved by an American X-ray contrast media manufacturer who has the largest market share in the world and started of pilot trials with the manufacturer. - Received order for commercial trials of Nitro Derivatives of Isophthalic acid from the largest manufacturer of X-ray contrast media manufacturer in the world. - The name of our Company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public limited company. 2020 -The Company has issued Bonus Shares in the Ratio of 1:1.

The Company was incorporated as Arvee Laboratories (India) Private Limited under the provisions of the Companies Act, 1956 vide certificate of incorporation dated January 27, 2012 in Ahmedabad, Gujarat. Subsequently, the name of the company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public company vide shareholder's approval dated September 11, 2017 and vide fresh certificate of incorporation dated September 19, 2017. KEY EVENTS AND MILESTONES IN THE HISTORY OF THE COMPANY 2012 - The Company was incorporated as Arvee Laboratories (India) Private Limited. 2013 - Acquired land, building and machineries from Skylink Chemicals Private Limited and started manufacturing unit. - Started construction of its first plant for Thiophene Derivatives. - Completes construction and commissioning of its Thiophene Derivatives Plant. 2014 - Plant inspected and approved by leading India pharmaceutical manufacturer for supply of Thiophene Derivatives. - Started construction of plant for Sulfo and Nitro Derivatives of Isophthalic Acid. - Received ISO 9001:2008 accreditation for NABCB and DAKKS from TUV NORD. - Plant inspected and approved by an American X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer. - Plant inspected and approved by a European X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer. 2015 - Completed construction and commissioning of plant for Nitro Derivatives of Isophthalic Acid. - After receiving inspection approval, our Company gets order for yearly supply of Nitro Derivatives of Isophthalic Acid to leading contrast media manufacturer in the United States of America. - Export to United States of America (USA) started. - Plant inspected and approved by European manufacturer for supply of Thiophene Derivatives. - Export of Thiophene Derivatives started to Europe. 2016 - Receives internal approvals for our Nitro Derivatives of Isophthalic acid from leading XRay contrast media manufacturer in Europe. - Receive approval for our Sulfo Derivatives of Isophthalic acid from a large polymer manufacturer in the United States of America and received yearly order for supply of Sulfo Derivatives to the USA. - Crossed turnover of Rs. 25 crores. 2017 - Plant inspected and approved by an American X-ray contrast media manufacturer who has the largest market share in the world and started of pilot trials with the manufacturer. - Received order for commercial trials of Nitro Derivatives of Isophthalic acid from the largest manufacturer of X-ray contrast media manufacturer in the world. - The name of our Company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public limited company. 2020 -The Company has issued Bonus Shares in the Ratio of 1:1.

Read More

Parent Organisation

Arvee Laboratories (India) Ltd.

Founded

27/01/2012

Managing Director

Mr.Shalin Sudhakarbhai Patel

NSE Symbol

ARVEEEQ

FAQ

The current price of Arvee Laboratories (India) Ltd is

The 52-week high for Arvee Laboratories (India) Ltd is

The market capitalization of Arvee Laboratories (India) Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Arvee Laboratories (India) Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Arvee Laboratories (India) Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Arvee Laboratories (India) Ltd shares.

The CEO of Arvee Laboratories (India) Ltd is Mr.Shalin Sudhakarbhai Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT